Zobrazeno 1 - 10 of 257 pro vyhledávání: '"H Ring-Larsen"'
2
Interferon-α2b Therapy in Low-Activity Hepatitis C: A Pilot Study
Autor: K Skaug, O S De Muckadell, Peter Simmonds, H Bell, H B Krarup, H Ring-Larsen, E. Schrumpf, A Maeland, I. Nordøy, K. Elgjo, Peer Brehm Christensen, H H Samdal, B von der Lippe, U Tage-Jensen
Publikováno v: Scopus-Elsevier
Nordøy, I, Krarup, H B, Bell, H, Christensen, P B, Elgjo, K, von der Lippe, B, De Muckadell, O S, Maeland, A, Ring-Larsen, H, Samdal, H H, Simmonds, P, Skaug, K, Tage-Jensen, U & Schrumpf, E 1997, ' Interferon-alpha 2b therapy in low-activity hepatitis C: a pilot study ', Scandinavian Journal of Gastroenterology, vol. 32, no. 12, pp. 1256-60 .
Europe PubMed Central
Udgivelsesdato: 1997-Dec BACKGROUND: Many patients with chronic hepatitis C have long periods of normal or near-normal liver enzyme levels, even though histologic alterations have been confirmed. The recommendation today is not to treat this patient
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50ead27bfe740afab273319cf9a8f6e1
https://doi.org/10.3109/00365529709028156
Zobrazit plný text záznamu
4
Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin
Autor: A, Mangia, O, Dalgard, N, Minerva, H, Verbaan, D, Bacca, H, Ring-Larsen, M, Copetti, V, Carretta, V, Piazzolla, R, Cozzolongo, L, Mottola, A, Andriulli
Publikováno v: Alimentary pharmacologytherapeutics. 31(12)
The optimal dose of ribavirin to be used in combination with Peg-IFN in patients with HCV genotypes 2 and 3 undergoing short treatment has not been established.To explore the relationship between starting ribavirin doses, expressed as mg/kg body weig
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::eb05912c482af44b2928abd657a08e1a
https://pubmed.ncbi.nlm.nih.gov/20222909
Zobrazit plný text záznamu
5
Identification of patients with hereditary haemochromatosis by magnetic resonance imaging and spectroscopic relaxation time measurements
Autor: E. Christiansen, Otto M. Henriksen, J. Dalhøj, P. Wiggers, Carsten Thomsen, Per Christoffersen, H. Ring-Larsen
Publikováno v: Magnetic Resonance Imaging. 10:867-879
A total of 4302 healthy blood donors were screened for elevated serum ferritin and transferrin saturation. Fifteen had increased serum ferritin at a follow-up examination. Five relatives of these donors also entered the study. Eleven patients had ele
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffbed8cc69e9eac98bbf9ad37f3a1027
https://doi.org/10.1016/0730-725x(92)90440-b
Zobrazit plný text záznamu
6
Screening for haemochromatosis: prevalence among Danish blood donors
Autor: H. Kiær, Mogens Hørder, H. Ring‐Larsen, Ole Blaabjerg, J. Dalhøj, P. Hyltoft Petersen, P. Wiggers
Publikováno v: WIGGERS, P, DALHØJ, J, KIÆR, H, RING-LARSEN, H, PETERSEN, P HYLTOFT, BLAABJERG, O & HØRDER, M 1991, ' Screening for haemochromatosis : prevalence among Danish blood donors ', Journal of Internal Medicine, vol. 230, no. 3, pp. 265-270 . https://doi.org/10.1111/j.1365-2796.1991.tb00441.x
Hereditary haemochromatosis is an autosomal recessive disease that is genetically expressed by excessive accumulation of iron in the tissues, resulting in cirrhosis, diabetes mellitus, cardiomyopathy and hypogonadism. As the disease may be diagnosed
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5ea26eda89e851ef4bb19457bd02c30
https://doi.org/10.1111/j.1365-2796.1991.tb00441.x
Zobrazit plný text záznamu
7
Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis
Autor: L E Schmidt, H Ring-Larsen
Publikováno v: Current pharmaceutical design. 12(35)
Hepatorenal syndrome is a severe, but not uncommon complication of decompensated liver cirrhosis. In particular, the rapidly progressive form of hepatorenal syndrome (type 1) is associated with a dismal prognosis. Established hepatorenal syndrome has
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cd87e701f4afb04a28a349e2fba24c5
https://pubmed.ncbi.nlm.nih.gov/17168767
Zobrazit plný text záznamu
9
Natural history and etiology of liver disease in patients with previous community-acquired acute non-A, non-B hepatitis. A follow-up study of 178 Danish patients consecutively enrolled in The Copenhagen Hepatitis Acuta Programme in the period 1969-1987
Autor: K, Grønbaek, H B, Krarup, H, Møller, K, Krogsgaard, M, Franzmann, J, Sonne, H, Ring-Larsen, O, Dietrichson
Publikováno v: Journal of hepatology. 31(5)
Consecutive patients originally diagnosed with acute non-A, non-B hepatitis were followed up to assess the long-term morbidity and mortality and to re-evaluate the etiology in surviving patients.Follow-up was performed in 178 patients with acute non-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7826768739dbab68a3e97e4fa28a08ad
https://pubmed.ncbi.nlm.nih.gov/10580576
Zobrazit plný text záznamu
10
Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP)
Autor: H L, Janssen, G, Gerken, V, Carreño, P, Marcellin, N V, Naoumov, A, Craxi, H, Ring-Larsen, G, Kitis, J, van Hattum, R A, de Vries, P P, Michielsen, F J, ten Kate, W C, Hop, R A, Heijtink, P, Honkoop, S W, Schalm
Publikováno v: Hepatology (Baltimore, Md.). 30(1)
Interferon alfa (IFN-alpha) is the primary treatment for chronic hepatitis B. The standard duration of IFN-alpha therapy is considered 16 weeks; however, the optimal treatment length is still poorly defined. We evaluated the efficacy and acceptabilit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e55e1884379e5c0cfe61bbe404d76883
https://pubmed.ncbi.nlm.nih.gov/10385662
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje